Analysts rate Prothena Corporation plc (PRTA:NSD) with a Strong Buy rating and a $62 target

Bank of America Securities upgraded the PRTA stock price target from $45 to $65 and rates it as a buy.

Based on the Prothena Stock Forecast from 4 analysts, the average analyst PRTA stock price target is USD 62.00 over the next 12 months. Prothena Corporation plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of PRTA stock forecast is Slightly Bullish, which is based on 10 positive signals and 5 negative signals. At the last closing, Prothena stock price was USD 58.00Prothena stock price has changed by +26.69% over the past week, +30.02% over the past month and -18.09% over the last year.

The stock forecast from 6 Crowd Analysts, has the average Crowd Analyst target for Prothena Corporation plc at USD 49.00 over the next 12 months. Prothena Corporation plc’s average Crowd Analyst rating is a Hold.

 

About Prothena Corporation plc (PRTA:NSD):

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson’s disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. The company was founded in 2012 and is based in Dublin, Ireland.

 

Recent Analyst Ratings for PRTA’s stock price:

Maintains Oppenheimer Outperform USD 100 » USD 110 2022-09-29
Upgraded Bank of America Neutral » Buy USD 45 » USD 65 2022-09-28
Maintains RBC Royalbank Outperform USD 45 » USD 52 2022-09-28
Target Raised by JMP Securities USD 50 » USD 81 2022-09-28
Maintains JMP Securities Market Outperform USD 77 » USD 50 2022-05-25
Target Lowered by Citigroup USD 87 » USD 73 2022-02-18
Initiated by JMP Securities Outperform USD 77 2021-11-19
Target Raised by RBC Royalbank Outperform USD 59 » USD 82 2021-09-30
Target Raised Oppenheimer Outperform USD 90 » USD 100 2021-09-27
Initiated by Fox Advisors Overweight USD 14 2021-09-20
Target Raised Cantor Fitzgerald  Overweight USD 70 » USD 103 2021-09-17
Target Raised by Oppenheimer Outperform USD 82 » USD 90 2021-09-14
Maintains Oppenheimer  Outperform USD 76 » USD 82 2021-08-09
Maintains RBC Royalbank Outperform USD 50 » USD 59 2021-07-19
Maintains Citigroup Buy USD 57 » USD 72 2021-07-13
Maintains Oppenheimer Holdings Outperform USD 54 » USD 76 2021-07-13
Maintains HC Wainwright Buy USD 58 » USD 75 2021-07-13
Upgraded by Bank of America UP » Neutral USD 12 » USD 49 2021-06-18
Target Raised by RBC Royalbank Outperform USD 28 » USD 50 2021-06-11
Reiterated by HC Wainwright Buy USD 33 » USD 58 2021-06-10
Target Raised by Oppenheimer Holdings Positive » Outperform USD 45 » USD 54 2021-06-08
Target Raised Cantor Fitzgerald Overweight USD 43 » USD 62 2021-06-08
Target Raised Oppenheimer Outperform USD 40 » USD 45 2021-06-01
Initiates Coverage On Citigroup Buy USD 39 2021-05-26
Target Raised Oppenheimer Outperform USD 35 » USD 40 2021-05-12

 

What we like:

High market capitalization:

PRTA stock is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns:

PRTA stock has performed well, on a risk adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity:

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization:

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets:

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow:

Prothena stock had positive total cash flow in the most recent four quarters.

Positive free cash flow:

Prothena stock had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth:

PRTA stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth:

PRTA stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio:

PRTA stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

 

What we don’t like:

High volatility:

The total returns for Prothena stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings:

PRTA stock price is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value:

PRTA stock price is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis:

PRTA stock price is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis:

PRTA stock price is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.